Evidence map›Paper›PMID 36522337›Full record

ArticleNature communications2022

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron.

Minfeng Huo, Zhimin Tang, Liying Wang, Linlin Zhang, Haiyan Guo, Yu Chen, Ping Gu, Jianlin Shi

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Bifunctional MXene-Augmented Retinal Progenitor Cell Transplantation for Retinal Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Minfeng Huo *Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, 200072, Shanghai, P. R. China.ORCID 0000-0001-5717-1845
Zhimin Tang *Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 200011, Shanghai, P.R. China.
Liying WangShanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, 200072, Shanghai, P. R. China.
Linlin ZhangState Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics Chinese Academy of Sciences; Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), 200050, Shanghai, P. R. China.
Haiyan GuoDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, P. R. China.
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, 200444, Shanghai, P.R. China.ORCID 0000-0002-8206-3325
Ping GuCentre of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, 100049, Beijing, P. R. China. guping2009@sjtu.edu.cn.ORCID 0000-0001-7681-1043
Jianlin ShiShanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, 200072, Shanghai, P. R. China. jlshi@mail.sic.ac.cn.ORCID 0000-0001-8790-195X
Tongji University · CNShanghai Jiao Tong University · CNChinese Academy of Sciences · CNFirst Affiliated Hospital of Zhengzhou University · CNShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distressing and lethal cardiotoxicity is one of the major severe side effects of using anthracycline drugs such as doxorubicin for cancer chemotherapy. The currently available strategy to counteract these side effects relies on the administration of cardioprotective agents such as Dexrazoxane, which unfortunately has unsatisfactory efficacy and produces secondary myelosuppression. In the present work, aiming to target the characteristic ferrous iron overload in the doxorubicin-contaminated cardiac microenvironment, a biocompatible nanomedicine prepared by the polyvinylpyrrolidone-directed assembly of magnesium hexacyanoferrate nanocatalysts is designed and constructed for highly efficient intracellular ferrous ion capture and antioxidation. The synthesized magnesium hexacyanoferrate nanocatalysts display prominent superoxide radical dismutation and catalytic H

Indexed as

CardiotoxicityMagnesiumCardiotonic AgentsDoxorubicinFerrocyanidesHumansHydrogen PeroxideIronCardiotonic AgentsDoxorubicinFerrocyanideshexacyanoferrate IIHydrogen PeroxideIronMagnesium

Identifiers

PMID36522337
PMCPMC9755285
OpenAlexW4311760377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.